



Legal Division - Patent Department  
J. Michael Dixon  
Pfizer Inc  
2800 Plymouth Road  
Ann Arbor, MI 48105  
Tel 734 622 1705 Fax 734 622 1553

IAP9 Rec'd PCT/PTO 18 MAY 2006

European Patent Office  
D-80298 Munich  
Fax No. 49892399-4465  
Authorized Officer: Zellner, A

April 14, 2005

Re: International Application No. PCT/IB2004/003668  
Warner-Lambert Company LLC  
Docket No. PC26158

RESPONSE TO WRITTEN OPINION OF  
INTERNATIONAL SEARCHING AUTHORITY

Dear Sirs,

This communication is being submitted in response to the Written Opinion of the International Preliminary Examining Authority ("IPEA"). The IPEA has rejected claims 1, 4, 5 and 6 as lacking novelty in view of references D1-D4. Claim 9 is being treated as a method claim and is rejected as lacking utility. The IPEA has stated that the remaining claims are novel and possess an inventive step in light of references D1-D6.

In order to advance the prosecution of this application, claims 1 and 9 have been amended. The definition for R<sup>1</sup> has been amended to exclude halogen. R<sup>1</sup> must now be represented by a haloalkyl or haloalkoxy moiety. The claims only read on 2-amino-5-cyano-pyridines that are further substituted at positions 3 or 4 with a haloalkyl or haloalkoxy moiety. Position 6 of the pyridine core may still be optionally be substituted with a halogen. It is respectfully submitted this amendment removes any overlap with references D1-D4.

Claim 9 has now been converted into a Swiss-use claim. Substitute sheets 37 - 40 reflecting the amendments described above accompany this report. An International Preliminary Examination Report confirming the patentability of claims 1-14 is hereby requested.

Respectfully submitted,


4/14/05  
Date  
Warner-Lambert Company  
Patent Department (421W)  
2800 Plymouth Road  
Ann Arbor, MI 48105  
(734) 622-1705

J. Michael Dixon  
Attorney for Applicant(s)  
Reg. No. 32,410

## CLAIMS

What is claimed is:

1. A compound of the formula:



5

and the pharmaceutically acceptable salts, hydrates, and prodrugs thereof, wherein;

- a) R¹ is represented by (C₁-C₂)alkyl, substituted with one or more halogens, or (C₁-C₂)alkoxy, substituted with one or more halogens,
- b) R² is represented by hydrogen or halogen,
- c) X¹ and X² are each independently represented by
- i) (C₁-C₁₂)alkyl, optionally substituted,
  - ii) (C₂-C₁₂)alkenyl, optionally substituted,
  - iii) (C₂-C₁₂)alkynyl, optionally substituted,
  - iv) (C₃-C₁₀)cycloalkyl, optionally substituted,
  - v) (C₃-C₁₀)cycloalkyl(C₁-C₆)alkyl, in which the alkyl and cycloalkyl moieties may each be optionally substituted,
  - vi) (C₆-C₁₀)aryl, optionally substituted,
  - vii) (C₆-C₁₀)aryl(C₁-C₆)alkyl, in which both the alkyl and aryl moieties may be optionally substituted,
  - viii) -(CH₂)q-CH₂-ZH, in which Z is S or O and q is an integer from 1-11,
  - ix) -(CH₂)n-Y-(CH₂)p-CH₃, in which Y is O or S, n is an integer from 1 to 4, and p is an integer from 1 to 4,
  - x) -[CH₂]m-C(O)R³, in which m is an integer selected from 1 to 8 and R³ is represented by hydrogen, (C₁-C₁₂)alkyl, (C₆-C₁₀)aryl, or (C₆-C₁₀)aryl(C₁-C₆)alkyl, in which both the alkyl and aryl moieties may be optionally substituted,
  - xi) -[CH₂]m-C(O)-O-R⁴, in which m is as defined above and R⁴ is represented by hydrogen, (C₁-C₁₂)alkyl, (C₆-C₁₀)aryl, or

30

- (C<sub>6</sub>-C<sub>10</sub>)aryl(C<sub>1</sub>-C<sub>6</sub>)alkyl, in which the alkyl and aryl moieties may be optionally substituted,
- xii)  $-\text{[CH}_2\text{]}_m\text{-C(O)-NR}^5\text{R}^6$  in which m is as described above, and R<sup>5</sup> and R<sup>6</sup> are each independently represented by hydrogen, (C<sub>1</sub>-C<sub>12</sub>)alkyl, (C<sub>6</sub>-C<sub>10</sub>)aryl, or (C<sub>6</sub>-C<sub>10</sub>)aryl(C<sub>1</sub>-C<sub>6</sub>)alkyl, in which the alkyl and aryl moieties may each be optionally substituted,
- i) heteroaryl, optionally substituted,
- ii) heteroaryl(C<sub>1</sub>-C<sub>6</sub>)alkyl, in which the heteroaryl and alkyl moieties may each be optionally substituted,
- iii) heterocyclic, optionally substituted, or,
- iv) heterocyclic(C<sub>1</sub>-C<sub>6</sub>)alkyl, in which the alkyl and heterocyclic moieties may each be optionally substituted.
2. A compound according to claim 1 in which R<sup>1</sup> is represented by trifluomethyl.
3. A compound according to any one of claims 1- or 2 in which said trifluoromethyl is located at the 4-position of the pyridine ring.
4. A compound according to anyone of claims 1-3 in which R<sup>2</sup> is hydrogen.
5. A compound according to anyone of claims 1-4 in which X<sup>1</sup> is (C<sub>1</sub>-C<sub>12</sub>)alkyl and X<sub>2</sub> is (C<sub>6</sub>-C<sub>10</sub>)aryl(C<sub>1</sub>-C<sub>6</sub>)alkyl.
6. A compound according to anyone of claims 1-5 in which X<sup>1</sup> and X<sup>2</sup> are each (C<sub>1</sub>-C<sub>12</sub>)alkyl
7. A compound according to anyone of claims 1-6 in which X<sup>1</sup> is (C<sub>1</sub>-C<sub>12</sub>)alkyl and X<sub>2</sub> is (C<sub>3</sub>-C<sub>10</sub>)cycloalkyl(C<sub>1</sub>-C<sub>6</sub>)alkyl.
8. A compound according to claim 1 selected from the group consisting of (R)-(+)-6-[Methyl-(1-Phenyl-ethyl)-amino]-4-trifluoromethyl-nicotinonitrile,
- (R)-(+)-2-Chloro-6-[methyl-(1-phenyl-ethyl)-amino]-4-trifluoromethyl-nicotinonitrile,

- 5 6-[methyl-(1-phenyl-ethyl)-amino]-4-trifluoromethyl-nicotinonitrile,  
6-[methyl-(1-phenyl-ethyl)-amino]-4-trifluoromethoxy-nicotinonitrile,  
6-[methyl-(1-(4-fluorophenyl)-ethyl)-amino]-4-trifluoromethyl-nicotinonitrile,  
6-[methyl-(1-(3-hydroxyphenyl)-ethyl)-amino]-4-trifluoromethyl-  
nicotinonitrile,  
6-[butyl(1-(3-hydroxyphenyl)-ethyl)-amino]-4-trifluoromethoxy-  
nicotinonitrile,  
6-dipropylamino-4-trifluoromethyl-nicotinonitrile,  
2-chloro-6-dimethylamino-4-trifluoromethyl-nicotinonitrile,  
10 6-(hexyl-octyl-amino)-4-trifluoromethyl-nicotinonitrile,  
6-(sec-butyl-methyl-amino)-4-trifluoromethyl-nicotinonitrile,  
6-[butyl-(2-hydroxy-ethyl)-amino]-4-trifluoromethyl-nicotinonitrile,  
6-(butyl-methyl-amino)-4-trifluoromethyl-nicotinonitrile,  
6-(benzyl-methyl-amino)-4-trifluoromethyl-nicotinonitrile,  
15 6-(cyclohexyl-propyl-amino)-4-trifluoromethyl-nicotinonitrile,  
6-(cyclopropylmethyl-propyl-amino)-4-trifluoromethyl-nicotinonitrile,  
6-(sec-butyl-methyl-amino)-2-chloro-4-trifluoromethyl-nicotinonitrile,  
6-Dipropylamino-2-chloro-4-trifluoromethyl-nicotinonitrile,  
6-(propyl-methyl-amino)-2-chloro-4-trifluoromethyl-nicotinonitrile, and,  
20 6-(Butyl-methyl-amino)-2-chloro-4-trifluoromethyl-nicotinonitrile.
9. Use of a compound according to anyone of Claims 1-8 in the manufacture  
of medicament.
10. Use of a compound according to anyone of Claims 1-8 in the  
manufacture of a medicament for inhibiting activation of the androgen  
25 receptor.
11. A pharmaceutical composition comprising a compound according to any  
one of Claims 1-8 in admixture with 1, or more, pharmaceutically  
acceptable excipients.
12. A topical pharmaceutical formulation comprising a compound according to  
anyone of Claims 1-8 in admixture with 1, or more, pharmaceutically  
30 acceptable excipients suitable for dermal application.

13. An article of manufacture comprising a compound according to any one of Claims 1-8 packaged for retail distribution which advises a consumer how to utilize the compound to alleviate a condition selected from the group consisting of acne, alopecia, and oily skin.

5

14. Use of a compound according to any one of claims 1-8 in the manufacture of a medicament for alleviating a condition selected from the group consisting of hormone dependent cancers, benign hyperplasia of the prostate, acne, hirsutism, excess sebum, alopecia, premenstrual syndrome, lung cancer, precocious puberty, osteoporosis, hypogonadism, age-related decrease in muscle mass, and anemia.

10

15

Pfizer Confidential